Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand
US5885956A · kind A · utility
12Cited by
0References
9Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 14, 1992 |
| Grant date | Mar 23, 1999 |
| Priority date | — |
| Expiry date | Dec 14, 2012 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/495
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for treating diabetes mellitus by administering composition providing a gastrin/CCK receptor ligand, e.g. a gastrin, and an EGF receptor ligand, e.g. TGF.alpha., in an amount sufficient to effect differentiation of pancreatic islet precursor cells to mature insulin-secreting cells. The composition can be administered systemically or expressed in situ by cells transgenically supplemented with one or both of a gastrin/CCK receptor ligand gene, e.g. a preprogastrin peptide precursor gene and an EGF receptor ligand gene, e.g. a TGF.alpha. gene.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.